Bench to bedside: A role for erythropoietin in sepsis

Critical Care

Volumn 14, Issue 4, 2010, Pages

  Walden, Andrew P ^a   Young, J Duncan ^a   Sharples, Edward ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ARA 290; ERYTHROPOIETIN; HYPERTENSIVE FACTOR; UNCLASSIFIED DRUG;

ANEMIA; APOPTOSIS; CELL DEATH; CELL PROTECTION; CLINICAL RESEARCH; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; HEMATOPOIESIS; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEPSIS; ANIMAL; BLOOD VESSEL; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; APOPTOSIS; BLOOD VESSELS; ERYTHROPOIETIN; HUMANS; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 79951526269     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9049     Document Type: Review

References (103)

1. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150. 10.1056/NEJMra021333, 12519925.
2. Russell JA. Management of sepsis. N Engl J Med 2006, 355:1699-1713. 10.1056/NEJMra043632, 17050894.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
4. Letarte J, Longo CJ, Pelletier J, Nabonne B, Fisher HN. Patient characteristics and costs of severe sepsis and septic shock in Quebec. J Crit Care 2002, 17:39-49. 10.1053/jcrc.2002.33028, 12040548.
5. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001, 29(7 Suppl):S121-S125. 10.1097/00003246-200107001-00037, 11445746.
6. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995, 23:1294-1303. 10.1097/00003246-199507000-00021, 7600840.
7. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008, 358:111-124. 10.1056/NEJMoa071366, 18184957.
8. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE, Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buchman TG, Karl IE. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001, 166:6952-6963.
9. Meakins JL, Pietsch JB, Bubenick O, Kelly R, Rode H, Gordon J, MacLean LD. Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg 1977, 186:241-250. 1396336, 142452, 10.1097/00000658-197709000-00002.
10. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 2001, 16:83-96. 10.1097/00024382-200116020-00001, 11508871.
11. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005, 6:484-494. 10.1038/nrn1687, 15928718.
12. Ghezzi P, Mengozzi M. Activities of erythropoietin on tumors: an immunological perspective. Eur J Immunol 2007, 37:1427-1430. 10.1002/eji.200737401, 17506033.
13. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008, 141:14-31. 10.1111/j.1365-2141.2008.07014.x, 18324962.
14. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol 1997, 61:375-380.
15. Matute-Bello G, Liles WC, Radella F, Steinberg KP, Ruzinski JT, Jonas M, Chi EY, Hudson LD, Martin TR. Neutrophil apoptosis in the acute respiratory distress syndrome. Am J Respir Crit Care Med 1997, 156:1969-1977.
16. Jimenez MF, Watson RW, Parodo J, Evans D, Foster D, Steinberg M, Rotstein OD, Marshall JC. Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch Surg 1997, 132:1263-1269; discussion 1269-1270.
17. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999, 27:1230-1251. 10.1097/00003246-199907000-00002, 10446814.
18. Remick DG. Pathophysiology of sepsis. Am J Pathol 2007, 170:1435-1444. 1854939, 17456750, 10.2353/ajpath.2007.060872.
19. Cheadle WG, Pemberton RM, Robinson D, Livingston DH, Rodriguez JL, Polk HC. Lymphocyte subset responses to trauma and sepsis. J Trauma 1993, 35:844-849. 10.1097/00005373-199312000-00007, 8263980.
20. Le Tulzo Y, Pangault C, Gacouin A, Guilloux V, Tribut O, Amiot L, Tattevin P, Thomas R, Fauchet R, Drenou B. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002, 18:487-494. 10.1097/00024382-200212000-00001, 12462554.
21. Hotchkiss RS, Chang KC, Grayson MH, Tinsley KW, Dunne BS, Davis CG, Osborne DF, Karl IE. Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc Natl Acad Sci USA 2003, 100:6724-6729. 164514, 12736377, 10.1073/pnas.1031788100.
22. Chung CS, Song GY, Lomas J, Simms HH, Chaudry IH, Ayala A. Inhibition of Fas/Fas ligand signaling improves septic survival: differential effects on macrophage apoptotic and functional capacity. J Leukoc Biol 2003, 74:344-351. 10.1189/jlb.0102006, 12949237.
23. Chung CS, Yang S, Song GY, Lomas J, Wang P, Simms HH, Chaudry IH, Ayala A. Inhibition of Fas signaling prevents hepatic injury and improves organ blood flow during sepsis. Surgery 2001, 130:339-345. 10.1067/msy.2001.116540, 11490369.
24. Hotchkiss RS, Swanson PE, Knudson CM, Chang KC, Cobb JP, Osborne DF, Zollner KM, Buchman TG, Korsmeyer SJ, Karl IE. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol 1999, 162:4148-4156.
25. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, Xanthoudakis S, Roy S, Black C, Grimm E, Aspiotis R, Han Y, Nicholson DW, Karl IE. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000, 1:496-501. 10.1038/82741, 11101871.
26. Kawasaki M, Kuwano K, Hagimoto N, Matsuba T, Kunitake R, Tanaka T, Maeyama T, Hara N. Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspase inhibitor. Am J Pathol 2000, 157:597-603. 1850133, 10934162.
27. Frey EA, Finlay BB. Lipopolysaccharide induces apoptosis in a bovine endothelial cell line via a soluble CD14 dependent pathway. Microb Pathog 1998, 24:101-109. 10.1006/mpat.1997.0178, 9480792.
28. Sylte MJ, Corbeil LB, Inzana TJ, Czuprynski CJ. Haemophilus somnus induces apoptosis in bovine endothelial cells in vitro. Infect Immun 2001, 69:1650-1660. 98069, 11179340, 10.1128/IAI.69.3.1650-1660.2001.
29. Hu X, Yee E, Harlan JM, Wong F, Karsan A. Lipopolysaccharide induces the antiapoptotic molecules, A1 and A20, in microvascular endothelial cells. Blood 1998, 92:2759-2765.
30. Menzies BE, Kourteva I. Internalization of Staphylococcus aureus by endothelial cells induces apoptosis. Infect Immun 1998, 66:5994-5998. 108759, 9826383.
31. Pohlman TH, Harlan JM. Human endothelial cell response to lipopolysaccharide, interleukin-1, and tumor necrosis factor is regulated by protein synthesis. Cell Immunol 1989, 119:41-52. 10.1016/0008-8749(89)90222-0, 2784080.
32. Hotchkiss RS, Tinsley KW, Swanson PE, Karl IE. Endothelial cell apoptosis in sepsis. Crit Care Med 2002, 30(5 Suppl):S225-S228. 10.1097/00003246-200205001-00009, 12004240.
33. Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, Garzotto M, McLoughlin M, Gallily R, Edwards CK, Schuchman EH, Fuks Z, Kolesnick R. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med 1997, 186:1831-1841. 2199151, 9382882, 10.1084/jem.186.11.1831.
34. Hofer S, Brenner T, Bopp C, Steppan J, Lichtenstern C, Weitz J, Bruckner T, Martin E, Hoffmann U, Weigand MA. Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunction. Crit Care 2009, 13:R93. 2717465, 19538738, 10.1186/cc7923.
35. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003, 228:1-14.
36. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986, 2:1175-1178. 10.1016/S0140-6736(86)92192-6, 2877323.
37. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987, 316:73-78. 10.1056/NEJM198701083160203, 3537801.
38. Hewitson KS, McNeill LA, Schofield CJ. Modulating the hypoxia-inducible factor signaling pathway: applications from cardiovascular disease to cancer. Curr Pharm Des 2004, 10:821-833. 10.2174/1381612043452884, 15032687.
39. Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 2002, 22:503-514. 10.1097/00004647-200205000-00001, 11973422.
40. Chong ZZ, Kang JQ, Maiese K. Angiogenesis and plasticity: role of erythropoietin in vascular systems. J Hematother Stem Cell Res 2002, 11:863-871. 10.1089/152581602321080529, 12590701.
41. Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 2004, 22:105-119.
42. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998, 95:4635-4640. 22542, 9539790, 10.1073/pnas.95.8.4635.
43. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005, 293:90-95. 2254180, 15632341, 10.1001/jama.293.1.90.
44. Sharples EJ, Yaqoob MM. Erythropoietin in experimental acute renal failure. Nephron Exp Nephrol 2006, 104:e83-e88. 10.1159/000094546, 16837817.
45. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305:239-242. 10.1126/science.1098313, 15247477.
46. Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, Doni M, Mengozzi M, Tonelli R, Ghezzi P, Coleman T, Brines M, Cerami A, Latini R. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 2005, 102:2046-2051. 548534, 15671158, 10.1073/pnas.0409329102.
47. Coleman TR, Westenfelder C, Togel FE, Yang Y, Hu Z, Swenson L, Leuvenink HG, Ploeg RJ, d'Uscio LV, Katusic ZS, Ghezzi P, Zanetti A, Kaushansky K, Fox NE, Cerami A, Brines M. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci USA 2006, 103:5965-5970. 1458681, 16585502, 10.1073/pnas.0601377103.
48. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008, 105:10925-10930. 2504825, 18676614, 10.1073/pnas.0805594105.
49. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001, 345:588-595. 10.1056/NEJMra002709, 11529214.
50. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32:858-873. 10.1097/01.CCM.0000117317.18092.E4, 15090974.
51. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001, 27:1416-1421. 10.1007/s001340101014, 11511958.
52. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008, 358:877-887. 10.1056/NEJMoa067373, 18305265.
53. Maschio G. Erythropoietin and systemic hypertension. Nephrol Dial Transplant 1995, 10(Suppl 2):74-79.
54. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003, 59:538-548. 10.1016/S0008-6363(03)00468-1, 14499855.
55. Neusser M, Tepel M, Zidek W. Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res 1993, 27:1233-1236. 10.1093/cvr/27.7.1233, 8252582.
56. Akimoto T, Kusano E, Fujita N, Okada K, Saito O, Ono S, Ando Y, Homma S, Saito T, Asano Y. Erythropoietin modulates angiotensin II- or noradrenaline-induced Ca(2+) mobilization in cultured rat vascular smooth-muscle cells. Nephrol Dial Transplant 2001, 16:491-499. 10.1093/ndt/16.3.491, 11239021.
57. Barrett JD, Zhang Z, Zhu JH, Lee DB, Ward HJ, Jamgotchian N, Hu MS, Fredal A, Giordani M, Eggena P. Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. J Hypertens 1998, 16(12 Pt 1):1749-1757. 10.1097/00004872-199816120-00007, 9869008.
58. Kusano E, Akimoto T, Umino T, Yanagiba S, Inoue M, Ito C, Ando Y, Asano Y. Modulation of endothelin-1-induced cytosolic free calcium mobilization and mitogen-activated protein kinase activation by erythropoietin in vascular smooth muscle cells. Kidney Blood Press Res 2001, 24:192-200. 10.1159/000054227, 11528212.
59. Akimoto T, Kusano E, Muto S, Fujita N, Okada K, Saito T, Komatsu N, Ono S, Ebata S, Ando Y, Homma S, Asano Y. The effect of erythropoietin on interleukin-1β mediated increase in nitric oxide synthesis in vascular smooth muscle cells. J Hypertens 1999, 17:1249-1256. 10.1097/00004872-199917090-00003, 10489101.
60. Kusano E, Akimoto T, Inoue M, Masunaga Y, Umino T, Ono S, Ando Y, Homma S, Muto S, Komatsu N, Asano Y. Human recombinant erythropoietin inhibits interleukin-1β-stimulated nitric oxide and cyclic guanosine monophosphate production in cultured rat vascular smooth-muscle cells. Nephrol Dial Transplant 1999, 14:597-603. 10.1093/ndt/14.3.597, 10193805.
61. Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991, 39:259-265. 10.1038/ki.1991.31, 2002640.
62. Buemi M, Allegra A, Squadrito F, Buemi AL, Lagana A, Aloisi C, Frisina N. Effects of intravenous administration of recombinant human erythropoietin in rats subject to hemorrhagic shock. Nephron 1993, 65:440-443. 10.1159/000187526, 8289996.
63. Miyashita K, Itoh H, Sawada N, Fukunaga Y, Sone M, Yamahara K, Yurugi T, Nakao K. Adrenomedullin promotes proliferation and migration of cultured endothelial cells. Hypertens Res 2003, 26(Suppl):S93-S98. 10.1291/hypres.26.S93, 12630817.
64. Hand MF, Haynes WG, Johnstone HA, Anderton JL, Webb DJ. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 1995, 48:806-813. 10.1038/ki.1995.354, 7474668.
65. Allegra A, Galasso A, Siracusano L, Aloisi C, Corica F, Lagana A, Frisina N, Buemi M. Administration of recombinant erythropoietin determines increase of peripheral resistances in patients with hypovolemic shock. Nephron 1996, 74:431-432. 10.1159/000189352, 8893173.
66. Tascilar O, Cakmak GK, Tekin IO, Emre AU, Ucan BH, Bahadir B, Acikgoz S, Irkorucu O, Karakaya K, Balbaloglu H, Kertis G, Ankarali H, Comert M. Protective effects of erythropoietin against acute lung injury in a rat model of acute necrotizing pancreatitis. World J Gastroenterol 2007, 13:6172-6182. 10.3748/wjg.13.6172, 18069756.
67. Cuzzocrea S, Di Paola R, Mazzon E, Patel NS, Genovese T, Muia C, Crisafulli C, Caputi AP, Thiemermann C. Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 2006, 34:1168-1177. 10.1097/01.CCM.0000207346.56477.E8, 16484922.
68. Koroglu TF, Yilmaz O, Ozer E, Baskin H, Gokmen N, Kumral A, Duman M, Ozkan H. Erythropoietin attenuates lipopolysaccharide-induced splenic and thymic apoptosis in rats. Physiol Res 2006, 55:309-316.
69. Mitra A, Bansal S, Wang W, Falk S, Zolty E, Schrier RW. Erythropoietin ameliorates renal dysfunction during endotoxaemia. Nephrol Dial Transplant 2007, 22:2349-2353. 10.1093/ndt/gfm216, 17438005.
70. Kao R, Xenocostas A, Rui T, Yu P, Huang W, Rose J, Martin CM. Erythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis model. Crit Care 2007, 11:R58. 2206412, 17509156, 10.1186/cc5920.
71. Aoshiba K, Onizawa S, Tsuji T, Nagai A. Therapeutic effects of erythropoietin in murine models of endotoxin shock. Crit Care Med 2009, 37:889-898. 10.1097/CCM.0b013e31819b8371, 19237893.
72. Katz O, Gil L, Lifshitz L, Prutchi-Sagiv S, Gassmann M, Mittelman M, Neumann D. Erythropoietin enhances immune responses in mice. Eur J Immunol 2007, 37:1584-1593. 10.1002/eji.200637025, 17458859.
73. Bryl E, Mysliwska J, Debska-Slizien A, Trzonkowski P, Rachon D, Bullo B, Zdrojewski Z, Mysliwski A, Rutkowski B. Recombinant human erythropoietin stimulates production of interleukin 2 by whole blood cell cultures of hemodialysis patients. Artif Organs 1999, 23:809-816. 10.1046/j.1525-1594.1999.06177.x, 10491027.
74. Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001, 98:5181-5186. 33184, 11309490, 10.1073/pnas.081275298.
75. Prutchi-Sagiv S, Golishevsky N, Oster HS, Katz O, Cohen A, Naparstek E, Neumann D, Mittelman M. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?. Br J Haematol 2006, 135:660-672. 10.1111/j.1365-2141.2006.06366.x, 17107348.
76. Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 2003, 163:993-1000. 1868246, 12937140.
77. Abel J, Spannbrucker N, Fandrey J, Jelkmann W. Serum erythropoietin levels in patients with sepsis and septic shock. Eur J Haematol 1996, 57:359-363. 10.1111/j.1600-0609.1996.tb01393.x, 9003476.
78. Tamion F, Le Cam-Duchez V, Menard JF, Girault C, Coquerel A, Bonmarchand G. Erythropoietin and renin as biological markers in critically ill patients. Crit Care 2004, 8:R328-R335. 1065015, 15469576, 10.1186/cc2902.
79. Tamion F, Le Cam-Duchez V, Menard JF, Girault C, Coquerel A, Bonmarchand G. Serum erythropoietin levels in septic shock. Anaesth Intensive Care 2005, 33:578-584.
80. Hobisch-Hagen P, Wiedermann F, Mayr A, Fries D, Jelkmann W, Fuchs D, Hasibeder W, Mutz N, Klingler A, Schobersberger W. Blunted erythropoietic response to anemia in multiply traumatized patients. Crit Care Med 2001, 29:743-747. 10.1097/00003246-200104000-00009, 11373460.
81. Rogiers P, Zhang H, Leeman M, Nagler J, Neels H, Melot C, Vincent JL. Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997, 23:159-162. 10.1007/s001340050310, 9069000.
82. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Siren AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002, 8:495-505. 2040012, 12435860.
83. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, van Zonneveld AJ, Schoemaker RG, van Gilst WH, Zijlstra F, van Veldhuisen DJ. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006, 20:135-141. 10.1007/s10557-006-7680-5, 16761193.
84. Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial. Crit Care Med 2006, 34:1661-1667. 10.1097/01.CCM.0000217919.22155.85, 16607233.
85. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001, 57:411-418. 10.1007/s002280100324, 11599659.
86. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, Meier-Hellmann A, Nollet G, Peres-Bota D. Anemia and blood transfusion in critically ill patients. JAMA 2002, 288:1499-1507. 10.1001/jama.288.12.1499, 12243637.
87. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin MJ, Colton T. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002, 288:2827-2835. 10.1001/jama.288.22.2827, 12472324.
88. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007, 357:965-976. 10.1056/NEJMoa071533, 17804841.
89. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 2004, 11(Suppl 1):S37-S44. 10.1038/sj.cdd.4401450, 15243580.
90. Wu WT, Lin NT, Subeq YM, Lee RP, Chen IH, Hsu BG. Erythropoietin protects severe haemorrhagic shock-induced organ damage in conscious rats. Injury 2010, 41:818-824. 20045106, 10.1016/j.injury.2009.12.006.
91. Zarychanski R, Turgeon AF, McIntyre L, Fergusson DA. Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ 2007, 177:725-734. 1976638, 17823140.
92. Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Gubler KD, Enny C, Colton T, Corwin MJ. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999, 27:2346-2350. 10.1097/00003246-199911000-00004, 10579246.
93. Gabriel A, Kozek S, Chiari A, Fitzgerald R, Grabner C, Geissler K, Zimpfer M, Stockenhuber F, Bircher NG. High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma 1998, 44:361-367. 10.1097/00005373-199802000-00023, 9498512.
94. Georgopoulos D, Matamis D, Routsi C, Michalopoulos A, Maggina N, Dimopoulos G, Zakynthinos E, Nakos G, Thomopoulos G, Mandragos K, Maniatis A. Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. Crit Care 2005, 9:R508-R515. 1297615, 16277712, 10.1186/cc3786.
95. Silver M, Corwin MJ, Bazan A, Gettinger A, Enny C, Corwin HL. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebocontrolled trial. Crit Care Med 2006, 34:2310-2316. 10.1097/01.CCM.0000233873.17954.42, 16878035.
96. Still JM, Belcher K, Law EJ, Thompson W, Jordan M, Lewis M, Saffle J, Hunt J, Purdue GF, Waymack JP, DeClement F, Kagan R, Chen A. A double-blinded prospective evaluation of recombinant human erythropoietin in acutely burned patients. J Trauma 1995, 38:233-236. 10.1097/00005373-199502000-00015, 7869442.
97. van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000, 28:2773-2778. 10.1097/00003246-200008000-00015, 10966249.
98. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999, 340:409-417. 10.1056/NEJM199902113400601, 9971864.
99. Wiese L, Hempel C, Penkowa M, Kirkby N, Kurtzhals JA. Recombinant human erythropoietin increases survival and reduces neuronal apoptosis in a murine model of cerebral malaria. Malar J 2008, 7:3. 2257967, 18179698, 10.1186/1475-2875-7-3.
100. Bienvenu AL, Ferrandiz J, Kaiser K, Latour C, Picot S. Artesunate-erythropoietin combination for murine cerebral malaria treatment. Acta Trop 2008, 106:104-108. 10.1016/j.actatropica.2008.02.001, 18359468.
101. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584-590. 10.1056/NEJM199808273390903, 9718377.
102. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007, 369:381-388. 10.1016/S0140-6736(07)60194-9, 17276778.
103. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Benett CL, Langensiepen S, Hyde C, Engert E. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006, 3:CD003407.